|
WO2015130957A1
|
|
Heterocyclic inhibitors of the sodium channel
|
|
EP2961403A1
|
|
Heterocyclic inhibitors of the sodium channel
|
|
US2013231350A1
|
|
Solid dispersion formulations and methods of use thereof
|
|
WO2013131018A1
|
|
Biaryl inhibitors of the sodium channel
|
|
WO2012122274A1
|
|
Self-emulsifying formulations and methods of use thereof
|
|
CA2828610A1
|
|
Solid dispersion formulations and methods of use thereof
|
|
EP3009427A1
|
|
Benzimidazole inhibitors of the sodium channel
|
|
WO2012061926A1
|
|
Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
|
|
WO2011035159A1
|
|
Aryl sulphone derivatives as calcium channel blockers
|
|
CA2771592A1
|
|
Substituted heterocyclic derivatives for the treatment of pain and epilepsy
|
|
CA2722704A1
|
|
Cyclylamine derivatives as calcium channel blockers
|
|
CA2722706A1
|
|
Di-t-butylphenyl piperazines as calcium channel blockers
|
|
US2009298883A1
|
|
N-piperidinyl acetamide derivatives as calcium channel blockers
|
|
EP2155183A1
|
|
Amino acid derivatives as calcium channel blockers
|
|
US2009312346A1
|
|
Method for increasing the bioavailability of benzhydryl piperazine containing compounds
|
